Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enveric Biosciences, Inc.AMRH · Entity 8193 | Director | February 08, 2018 | February 13, 2018 |
| QUAKER CHEMICAL CORPKWR · Entity 4278 | SVP, CIDO | July 06, 2022 | July 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enveric Biosciences, Inc.
Report date February 08, 2018 · Filed February 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,164,713 |
Ending reported balance
After 2018-02-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-08 · Grant · Acquired 170,000 · Balance 1,159,792 F1: Represents shares of restricted stock granted to the Reporting as a bonus for services provided to the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan. Row 2 · 2018-02-09 · Other · Acquired 4,921 · Balance 1,164,713 F2: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted to the Reporting as a bonus for services provided to the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan.
F2: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person.
QUAKER CHEMICAL CORP
Report date July 06, 2022 · Filed July 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 238 |
Reported balance
After 2022-07-06 transaction · row 1
1 source rowRow 1 · 2022-07-06 · Grant · Acquired 238 · Balance 238 F1: This award represents time-based restricted stock and stock options granted to reporting person for the 2022-2024 Performance Period under the Company's 2016 Long-Term Performance Incentive Plan. The restricted stock vests on March 16, 2025 and the stock options are exercisable in three consecutive annual installments: 202 shares on March 16, 2023; 202 shares on March 16, 2024; and 202 shares on March 16, 2025. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.58 · Expires 2029-03-16 | Direct | 606 |
Reported balance
After 2022-07-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-06 · Grant · Acquired 606 · Balance 606 F1: This award represents time-based restricted stock and stock options granted to reporting person for the 2022-2024 Performance Period under the Company's 2016 Long-Term Performance Incentive Plan. The restricted stock vests on March 16, 2025 and the stock options are exercisable in three consecutive annual installments: 202 shares on March 16, 2023; 202 shares on March 16, 2024; and 202 shares on March 16, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This award represents time-based restricted stock and stock options granted to reporting person for the 2022-2024 Performance Period under the Company's 2016 Long-Term Performance Incentive Plan. The restricted stock vests on March 16, 2025 and the stock options are exercisable in three consecutive annual installments: 202 shares on March 16, 2023; 202 shares on March 16, 2024; and 202 shares on March 16, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2022 Filed Jul 8, 2022 20:10 UTC | QUAKER CHEMICAL CORP KWR · Entity 4278 | GrantEmployee Stock Option (right to buy) · Derivative | 606 | $0.00 Strike: $139.58 | $0.00 |
DisclosureSEC source: 0001209191-22-041620 · doc4.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · SVP, CIDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606 Underlying: Common Stock · 606 shares Expires 2029-03-16 F1 · derivative.exercise_date: This award represents time-based restricted stock and stock options granted to reporting person for the 2022-2024 Performance Period under the Company's 2016 Long-Term Performance Incentive Plan. The restricted stock vests on March 16, 2025 and the stock options are exercisable in three consecutive annual installments: 202 shares on March 16, 2023; 202 shares on March 16, 2024; and 202 shares on March 16, 2025. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 20:10 UTC | QUAKER CHEMICAL CORP KWR · Entity 4278 | GrantCommon Stock | 238 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041620 · doc4.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · SVP, CIDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238 F1 · shares: This award represents time-based restricted stock and stock options granted to reporting person for the 2022-2024 Performance Period under the Company's 2016 Long-Term Performance Incentive Plan. The restricted stock vests on March 16, 2025 and the stock options are exercisable in three consecutive annual installments: 202 shares on March 16, 2023; 202 shares on March 16, 2024; and 202 shares on March 16, 2025. Read SEC document |
| February 09, 2018 Filed Feb 13, 2018 01:18 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | OtherCommon Stock | 4,921 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000529 · form410211002rai_02122018.xml · nonDerivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,164,713 F2 · kind: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. F2 · price: Represents shares granted to the Reporting Person by the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan in connection with the resolution of 2017 directors' fee payments owed by the Issuer to the Reporting Person. Read SEC document |
| February 08, 2018 Filed Feb 13, 2018 01:18 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantCommon Stock | 170,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000529 · form410211002rai_02122018.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,792 F1 · price: Represents shares of restricted stock granted to the Reporting as a bonus for services provided to the Issuer pursuant to the Issuer's 2015 Equity Incentive Award Plan. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:49 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-18-000050 · form410211002rai_01032018.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,680 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 21:49 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 7,680 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-18-000050 · form410211002rai_01032018.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 989,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. On January 1, 2018, the RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 19:46 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-002954 · form410211002_12262017.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 333,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2015 Equity Incentive Award Plan (the "Plan") on May 10, 2016 (the "2016 Grant"). Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The indicated RSUs vested in full on December 21, 2017, due to the determination of the Issuer to accelerate vesting of the RSUs in accordance with the terms of the Plan and a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2015 Equity Incentive Award Plan (the "Plan") on May 10, 2016 (the "2016 Grant"). Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The indicated RSUs vested in full on December 21, 2017, due to the determination of the Issuer to accelerate vesting of the RSUs in accordance with the terms of the Plan and a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2015 Equity Incentive Award Plan (the "Plan") on May 10, 2016 (the "2016 Grant"). Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The indicated RSUs vested in full on December 21, 2017, due to the determination of the Issuer to accelerate vesting of the RSUs in accordance with the terms of the Plan and a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2015 Equity Incentive Award Plan (the "Plan") on May 10, 2016 (the "2016 Grant"). Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The indicated RSUs vested in full on December 21, 2017, due to the determination of the Issuer to accelerate vesting of the RSUs in accordance with the terms of the Plan and a RSU Agreement between the Issuer and the Reporting Person. F2 · balance_after: The Reporting Person previously agreed to cancel 166,667 RSUs granted pursuant to the 2016 Grant. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 19:46 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 333,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-002954 · form410211002_12262017.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 982,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2015 Equity Incentive Award Plan (the "Plan") on May 10, 2016 (the "2016 Grant"). Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The indicated RSUs vested in full on December 21, 2017, due to the determination of the Issuer to accelerate vesting of the RSUs in accordance with the terms of the Plan and a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:21 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | PurchaseWarrant (Right to Buy) · Derivative | 145,450 | $0.01 Strike: $4.12 | $1,454.50 |
DisclosureSEC source: 0000921895-17-002743 · form410211rai_11212017.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,450 Underlying: Common Stock · 145,450 shares Expires 2022-11-21 F1 · security: The warrant gives the Reporting Person the right to purchase up to 145,450 shares of common stock at an exercise price equal to $4.115 per share. The warrant will expire on November 21, 2022. Read SEC document |
| November 17, 2017 Filed Nov 21, 2017 21:21 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | PurchaseCommon Stock | 145,450 | $4.12 | $598,526.75 |
DisclosureSEC source: 0000921895-17-002743 · form410211rai_11212017.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 648,779 Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:28 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 3,329 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001624 · form410211002f_05232017.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · security: On May 19, 2017, 3,329 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_price: On May 19, 2017, 3,329 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.exercise_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.exercise_date: On May 19, 2017, 3,329 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. F1 · derivative.expiration_date: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · derivative.expiration_date: On May 19, 2017, 3,329 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| May 19, 2017 Filed May 23, 2017 22:28 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 3,329 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001624 · form410211002f_05232017.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: As previously disclosed in filings with the Securities and Exchange Commission, represents stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full based on the terms of a Restricted Stock Unit Agreement between the Issuer and the Reporting Person. F2 · price: On May 19, 2017, 3,329 shares of the Issuer's common stock were issued in settlement of the RSUs described in footnote (1) above. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:14 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionRestricted Stock Unit · Derivative | 5,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001274 · form410211002f_05032017.xml · derivative · entry 3 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,121 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:14 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Tax withholdingCommon Stock | 1,792 | $6.59 | $11,809.28 |
DisclosureSEC source: 0000921895-17-001274 · form410211002f_05032017.xml · nonDerivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,329 F2 · shares: Represents number of shares withheld by the Issuer for the payment of taxes. No shares of Common Stock were sold by the Reporting Person in connection with this transaction. The Reporting Person will retain the net number of shares issued upon the settlement of the RSUs. F3 · price: Closing market price of the Issuer's common stock on the transaction date. Read SEC document |
| May 01, 2017 Filed May 3, 2017 22:14 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Exercise / conversionCommon Stock | 5,121 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000921895-17-001274 · form410211002f_05032017.xml · nonDerivative · entry 1 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 505,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents restricted stock units ("RSUs") granted as incentive compensation pursuant to the Issuer's 2015 Equity Incentive Award Plan. Each RSU represents the right to receive, at settlement, one share of the Issuer's common stock. The RSUs vested in full on May 1, 2017, based on the terms of a RSU Agreement between the Issuer and the Reporting Person. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:37 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 7,680 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001064 · form410211002g_04142017.xml · derivative · entry 3 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,680 Underlying: Common Stock · 7,680 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. F3 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on January 1, 2018. Read SEC document |
| April 11, 2017 Filed Apr 14, 2017 20:37 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | GrantRestricted Stock Unit · Derivative | 5,121 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-17-001064 · form410211002g_04142017.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,121 Underlying: Common Stock · 5,121 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. F2 · derivative.expiration_date: These Restricted Stock Units are scheduled to vest on May 1, 2017. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 21:04 UTC | Enveric Biosciences, Inc. AMRH · Entity 8193 | Purchase8% Convertible Note due March 2020 · Derivative | Not disclosed | $1,000,000.00 | $1,000,000.00 |
DisclosureSEC source: 0000921895-17-000591 · form410211002_03062017.xml · derivative · entry 2 Rai Dhruwa N · CIK 0001672632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2020-03-02 F1 · security: The Convertible Note bears interest at a rate of 8% per annum, with interest being paid annually on the first, second and third anniversaries of the issuance of the Convertible Note, beginning on March 2, 2018, and any unpaid principal and interest due on March 2, 2020. The unpaid amount of principal of the Convertible Note is convertible into shares of the Issuer's common stock at a conversion price of (i) in the event that any registration statement for the public offering of common stock filed by the Issuer with the U.S. Securities and Exchange Commission ("SEC") in connection with an uplisting to a national stock exchange is declared effective by the SEC on or prior to December 31, 2017, such price per share that is equal to 68% of the price per share of common stock offered and sold pursuant to such registration statement, or (continued) F2 · security: (Footnote 1 Continuation) (ii) if no such registration statement is declared effective by December 31, 2017, such price per share that is equal to the weighted average closing price per share of the Issuer's common stock for the 20 trading days immediately preceding December 31, 2017, subject to adjustment under certain circumstances. From and after an event of default and for so long as the event of default is continuing, the Convertible Note will bear default interest at the rate of 10% per annum. F1 · derivative.exercise_price: The Convertible Note bears interest at a rate of 8% per annum, with interest being paid annually on the first, second and third anniversaries of the issuance of the Convertible Note, beginning on March 2, 2018, and any unpaid principal and interest due on March 2, 2020. The unpaid amount of principal of the Convertible Note is convertible into shares of the Issuer's common stock at a conversion price of (i) in the event that any registration statement for the public offering of common stock filed by the Issuer with the U.S. Securities and Exchange Commission ("SEC") in connection with an uplisting to a national stock exchange is declared effective by the SEC on or prior to December 31, 2017, such price per share that is equal to 68% of the price per share of common stock offered and sold pursuant to such registration statement, or (continued) F2 · derivative.exercise_price: (Footnote 1 Continuation) (ii) if no such registration statement is declared effective by December 31, 2017, such price per share that is equal to the weighted average closing price per share of the Issuer's common stock for the 20 trading days immediately preceding December 31, 2017, subject to adjustment under certain circumstances. From and after an event of default and for so long as the event of default is continuing, the Convertible Note will bear default interest at the rate of 10% per annum. F1 · derivative.underlying_shares: The Convertible Note bears interest at a rate of 8% per annum, with interest being paid annually on the first, second and third anniversaries of the issuance of the Convertible Note, beginning on March 2, 2018, and any unpaid principal and interest due on March 2, 2020. The unpaid amount of principal of the Convertible Note is convertible into shares of the Issuer's common stock at a conversion price of (i) in the event that any registration statement for the public offering of common stock filed by the Issuer with the U.S. Securities and Exchange Commission ("SEC") in connection with an uplisting to a national stock exchange is declared effective by the SEC on or prior to December 31, 2017, such price per share that is equal to 68% of the price per share of common stock offered and sold pursuant to such registration statement, or (continued) F2 · derivative.underlying_shares: (Footnote 1 Continuation) (ii) if no such registration statement is declared effective by December 31, 2017, such price per share that is equal to the weighted average closing price per share of the Issuer's common stock for the 20 trading days immediately preceding December 31, 2017, subject to adjustment under certain circumstances. From and after an event of default and for so long as the event of default is continuing, the Convertible Note will bear default interest at the rate of 10% per annum. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.